Zepbound for sleep apnea: eligibility, care and costs

The FDA indication is moderate to severe OSA in adults with obesity. In the label’s clinical studies, OSA severity was defined by an apnea-hypopnea index of at least 15 events per hour and obesity by a body mass index of at least 30. These were trial entry definitions, not a do-it-yourself eligibility calculator. A clinician considers the actual report, symptoms, other conditions and treatment history.

If breathing symptoms have not been assessed, start with a sleep evaluation. Depending on the person, a clinician may use a technically adequate home apnea test or attended laboratory study. A negative or inconclusive home result does not reliably close the question when suspicion remains.

Two randomized, placebo-controlled 52-week studies enrolled a combined 469 adults with obesity and moderate to severe OSA. One study involved people unable or unwilling to use PAP; the other involved PAP users. The main measured endpoint was change in apnea-hypopnea index. Tirzepatide reduced breathing events more than placebo in the studied settings. The trials excluded people with type 2 diabetes, and the label reports too few participants aged 65 or older to determine whether their response differs. These are limits on trial generalizability, not additional label exclusion criteria.

That result is meaningful for the indicated condition, but it does not compare medicine against an optimized PAP plan or establish a universal replacement. The FDA label explicitly notes that the trials did not evaluate the timing or appropriateness of PAP discontinuation for people previously compliant with PAP. Ongoing symptoms and treatment response need follow-up, rather than assuming weight change alone proves apnea is resolved.

The label carries a boxed warning about thyroid C-cell tumors observed in rats. Zepbound is contraindicated for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, and for known serious hypersensitivity to tirzepatide or its ingredients. Common adverse reactions include nausea, diarrhea, vomiting and constipation. The label also warns about serious gastrointestinal reactions, dehydration-related acute kidney injury, gallbladder disease and pancreatitis.

A prescriber should review medical history, other medicines, pregnancy plans, side effects and follow-up. The label identifies 10 mg and 15 mg as OSA maintenance strengths; these are label facts, not a personal dose choice. Do not infer that a weight-management listing at another strength offers the same OSA service or ongoing care.

For any exact route, ask for the medicine presentation and strength, quantity and refill cadence; clinical consultation and follow-up charges; required testing, labs or supplies; delivery and any other mandatory fees; insurance or savings-program conditions; and every date at which money becomes due. A monthly headline or per-fill amount is not the full required cost if other services or commitments apply.

Coverage depends on the actual payer, plan and medical criteria. A cash program may have conditional prices, purchase deadlines, quantity rules or changing terms. Ask what happens if the clinician does not prescribe, the plan changes, a refill is delayed, a payment is missed or you cancel. Current exact-offer research has not established comparable complete totals or approved stars for the proposed OSA maintenance scenarios, so this guide names the questions rather than a winner.